Cryptocurrencies
Nuvalent Announces First Patient Dosed In ARROS-1 Phase 1/2 Clinical Trial Of NVL-520, Its Novel ROS1-selective Inhibitor
CAMBRIDGE, Mass., Jan. 7, 2022 /PRNewswire/ — Nuvalent, Inc. (Nasdaq: NUVL), a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the first patient has been dosed in ARROS-1, Read more…